DECISION related activities at EASL Congress 2024

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop (1) a reliable prognostic test to identify patients that are at risk for a poor outcome following standard therapy but who may benefit from a novel and personalised combinatorial therapy, and (2) a robust response test to predict the success of a novel combinatorial therapy as opposed to more aggressive solutions like a liver transplant.

Wednesday, 5th June, 13:30 – 14:00h CEST

Agenda:

• Brief intro to DECISION project
  Pierre-Emmanuel Rautou, DECISION coordinator
  13:30h CET – 4 minutes
• Plasma extracellular vesicles improve prediction of 90-day mortality in patients with acute decompensation of cirrhosis.
  Shantha Valainathan – 8 minutes
• Extensive characterization of new biomarkers associated with infection and outcome of decompensation of cirrhosis using high throughput metabolomics, lipidomics and cytokinomics.
  Cristina López-Vicario – 8 minutes
• Discussion + Conclusion
  Pierre-Emmanuel Rautou – 10 min

• 5^th June: Plasma extracellular vesicles improve prediction of 90-day mortality in patients with acute decompensation of cirrhosis. Shantha Valainathan, poster (poster ID: WED-112)
• 5^th June: Extensive characterization of new biomarkers associated with infection and outcome of decompensation of cirrhosis using high throughput metabolomics, lipidomics and cytokinomics. Cristina López-Vicario, poster (poster ID: TOP-073)

5^th June: Pierre-Emmanuel Rautou is organizing the postgraduate training course and giving the lecture at 17:45 – 19:15: The role of vascular biology in chronic liver disease: implications for clinical management – Vascular consequences of cirrhosis outside the liver (room: Gold Room)

• 6^th June, 14:00 – 15:00: Meet-the-Experts – Acute Liver Failure – non ACLF. Javier Fernández. (room: Meet-the-Experts 2)
• 7^th June, 8:30 – 9:30: Meet-the-Experts – Workup and management of liver transplantation in ALD. Thierry Gustot. (room: Meet-the-Experts 1)

• 6^th June, 17:15 – 17:30: The linoleic acid-derived leukotoxin 9,10-DiHOME drives immunosuppression in patients with acute-on-chronic liver failure. Bryan J. Contreras, oral presentation (room: Space 1+2; presentation ID: OS-011)
• 5^th June: Exploring the potential of human serum albumin to reprogram B cell function. Berta Romero-Grimaldo, poster (poster ID: WED-087)

7^th June, 17:15 – 18:30: Sophie Lotersztajn (INSERM) co-chairs the Abstract session – MASLD: Experimental

• 5^th June: Pavel Strnad (UKA) presents the poster “Patients with alpha-1-antitrypsin deficiency and the risk of developing liver events: a longitudinal cohort study” (poster ID: WED-138)
• 7^th June: Pavel Strnad (UKA) presents the poster “Proteomic analysis identified fazirsiran treatment-responsive protein biomarkers in patients with alpha-1 antitrypsin deficiency-associated liver disease” (poster ID: FRI-164)
• 7^th June: Pavel Strnad (UKA) presents the poster “Correlation of non-invasive tests with histological features and intrahepatic Z-alpha-1 antitrypsin burden in patients with alpha-1 antitrypsin deficiency-associated liver disease” (poster ID: FRI-161)
• 7^th June, 15 – 16:00: Pavel Strnad (UKA) co-chairs the symposium “New therapies in rare diseases” (room: Brown 3)
• 8^th June: Johanna Reißing (UKA) presents the poster “Th2 cell activation in chronic liver disease is driven by local IL-33 and contributes to IL-13 dependent fibrogenesis” (poster ID: SAT-545)

5^th June: Christophe Junot presents poster “Multi-compartment metabolomics for stratifying cirrhotic patients with acute decompensation” (poster ID: WED-083)

• 5^th June, 13:40 – 13:55: Paolo Caraceni speaks at “Grifols: Long term albumin to manage disease progression: latest evidence and upcoming results” and presents “How long, how much and to whom? Real world data from more than 5 years practice” (room: Space 3)
• 7^th June, 15:20 – 15:30: Paolo Caraceni speaks at interactive session “Management of acites in non-LT candidates” and presents “I would go for albumin” (room: EASL Studio & Hepatology Arena)
• 7^th June: Dr. Enrico Pompili (UNIBO) presents poster “Predictors of ascites resolution in patients with cirrhosis receiving long-term albumin treatment. Results from a real-world study in Italy (Real-ANSWER)” (poster ID FRI-047-YI)
• 7^th June: Dr. Giulia Iannone (UNIBIO) presents poster “Long-term albumin administration in outpatients with decompensated cirrhosis and diabetes mellitus: post-hoc analysis of the ANSWER Trial database” (Poster ID: FRI-078-YI)

• 5^th June: Lorena Paule: Role of apoptosis in B-cell compartment retraction during decompensation of cirrhosis and acute-on-chronic liver failure (Poster ID: WED-100-YI)
• 5^th June: Elisa Castillo: Comparative analysis of the gut-liver axis in preclinical models of decompensated cirrhosis (Poster ID: WED-530-YI)

5^th June: Kohilan Gananandan presents poster “Low-density lipoprotein can predict hospital readmissions and outcomes following acute decompensation of cirrhosis” (poster ID: WED-098-YI)

• 6^th June: Hepatic sarcoidosis diagnosis and management: an italian multicenter study. Cristina Della Corte, poster (poster ID: THU-161)
• 8^th June: Mild overt hepatic encephalopathy (HE) – more than meets the eye. Chiara Mangini, poster (poster ID: SAT-094-YI)

• 6^th June: A multi-center comparison of Atezolizumab plus Bevacizumab and Lenvatinib as primary systemic therapy for unresectable hepatocellar carcinoma: focus on thrombotic and hemorragic adverse events. Marco Tizzani, poster (Poster ID: THU-486-YI)
• 7^th June: Clinical impact of acute kidney disease in patients with decompensated cirrhosis: Insights from a prospective observational study on renal dysfunction. Alberto Calleri, poster (poster ID: FRI-056-YI)

• 7^th June, 8:30 – 8:45 am: Prediction of the risk of liver related events with non-invasive models is better than liver biopsy in MASLD cACLD patients. Laia Aceituno, oral presentation (room: Space 1+2; Presentation ID OS-047-YI)
• 7^th June, 8:30 – 9:45 am: Abstract session – Cirrhosis and its complications: Clinical. Joan Genescà, session co-chair. (room: Brown 3)
• 7^th June, 8:30 – 9:30 am: TIPS in alcohol-related hepatitis. Meritxell Ventura-Cots, session co-chair (room: EASL Studio & Hepatology Arena)

• 7th June, 17:15 – 17:30: Performance of spleen stiffness measurement by vibration-controlled transient elastography to rule out high-risk varices in patients with chronic extrahepatic portal vein obstruction without cirrhosis. Lucile Moga is speaker. (room: Amber 3+4)

• 5^th June, 8:55 – 9:05: Patient experiences in using health services/availability of health services. Milan Mishkovikj, speaker. Room: Amber 3+4
• 6^th June, 8:30 – 9:30: Developing successful nurse-led clinics – A multidisciplinary perspective. Marko Korenjak, co-speaker. Room: Meet-the-Expert 1

• 5^th June: Rifaximin-alpha acts through increased abundance of Lactobacillus spp. in murine models of chronic liver disease. Maximilian Brol. Poster ID: WED-548
• 7^th June, 14:10 – 14:50: Jonel Trebicka is co-speaker at “Interactive sessions / One table per participant”, which is part of “It’s all about the money: Toolkit to apply to European grants” (room: Amber 7)
• 8^th June, 8:45 – 9:00 am: Jonel Trebicka speaks at “Decompensated cirrhosis: is it about portal hypertension or systemic inflammation” and presents “Systemic inflammation across disease stages (pre/during/following decompensation)” (room: Brown 3)